A strategy to assess the cellular activity of E3 ligase components against neo-substrates using electrophilic probes.
E3 ligase
JQ1
SKP1
SOCS box family
SPSB2
VHL
covalent
dasatinib
electroporation
neo-substrate
targeted protein degradation (TPD)
Journal
Cell chemical biology
ISSN: 2451-9448
Titre abrégé: Cell Chem Biol
Pays: United States
ID NLM: 101676030
Informations de publication
Date de publication:
20 01 2022
20 01 2022
Historique:
received:
31
08
2020
revised:
17
06
2021
accepted:
20
08
2021
pubmed:
10
9
2021
medline:
3
3
2022
entrez:
9
9
2021
Statut:
ppublish
Résumé
While there are hundreds of predicted E3 ligases, characterizing their applications for targeted protein degradation has proved challenging. Here, we report a chemical biology approach to evaluate the ability of modified recombinant E3 ligase components to support neo-substrate degradation. Bypassing the need for specific E3 ligase binders, we use maleimide-thiol chemistry for covalent functionalization followed by E3 electroporation (COFFEE) in live cells. We demonstrate that electroporated recombinant von Hippel-Lindau (VHL) protein, covalently functionalized at its ligandable cysteine with JQ1 or dasatinib, induces degradation of BRD4 or tyrosine kinases, respectively. Furthermore, by applying COFFEE to SPSB2, a Cullin-RING ligase 5 receptor, as well as to SKP1, the adaptor protein for Cullin-RING ligase 1 F box (SCF) complexes, we validate this method as a powerful approach to define the activity of previously uncharacterized ubiquitin ligase components, and provide further evidence that not only E3 ligase receptors but also adaptors can be directly hijacked for neo-substrate degradation.
Identifiants
pubmed: 34499862
pii: S2451-9456(21)00396-2
doi: 10.1016/j.chembiol.2021.08.007
pii:
doi:
Substances chimiques
Recombinant Proteins
0
Ubiquitin-Protein Ligases
EC 2.3.2.27
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
57-66.e6Informations de copyright
Copyright © 2021 Elsevier Ltd. All rights reserved.
Déclaration de conflit d'intérêts
Declaration of interests All authors are or were employees of Novartis Pharma AG.